Clinical thais of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 2, 1997, Pages 161-166

  Cassidy, J ^a,c   Paul, J ^b   Soukop, M ^b   Habeshaw, T ^b   Reed, N S ^b   Parkin, D ^a   Kaye, S B ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Neurotoxicity; Nimodipine; Ovarian cancer

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; NIMODIPINE; PLACEBO; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING; ADULT; AGED; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; HEARING LOSS; MIDDLE AGED; OVARY TUMOR; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CALCIUM CHANNEL BLOCKERS; CISPLATIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEARING LOSS, BILATERAL; HUMANS; MIDDLE AGED; NAUSEA; NIMODIPINE; OVARIAN NEOPLASMS; PATIENT COMPLIANCE; PERIPHERAL NERVOUS SYSTEM DISEASES; TREATMENT FAILURE;

EID: 0031594875     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050723     Document Type: Article

References (21)

1. Kaye SB, Paul J, Cassidy J, et al. (1996) Mature results of a randomised trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 14: 2113-2119
2. Hamers FPT, Gerritsen van der Hoop R, Traber J, Neijt JP, Jennekens FGI, Gispens WH (1990). The calcium antagonist nimodipine in cisplatin induced neuropathy in the rat. Eur J Pharmacol 183: 1710-1711
3. Vermorken JB, Bokkel Huinink WW ten, Eisenhauer EA, Favalli G, Belpomme D, Conte PF, Kaye SB (1993) Carboplatin versus cisplatin. Ann Oncol 4 [Suppl 4]: 41-48
4. Soukop M (1990) A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 26 [Suppl 1]: 15-19
5. Thompson SW, Davis LE, Kornfield M, Hilgers RD, Standefer JC (1984) Cisplatin neuropathy, clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54: 1269-1275
6. Mollman JE, Glover DJ, Hogan WM, Furman RE (1988) Cisplatin neuropathy, risk factors, prognosis and protection by WR-2721. Cancer 61: 2192-2195
7. Mollman JE (1990) Cisplatin neurotoxicity N Engl J Med 322: 126-127
8. Gerritsen van der Hoop R, Vecht CJ, Burg MEL van der et al (1990) Prevention of cisplatin neurotoxicity with an ACTH (4-9) analogue in patients with ovarian cancer. N Engl J Med 322: 89-94
9. Hamers FPT, Brakkee JH, Cavalletti E, et al. (1993) Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 53: 544-549
10. Gilsbach JM, Reulen HJ Ljunggren B, Brandt L, Holst H van, Mokry M, Essen C von, Conzen MA (1990) Early aneurysm surgery and preventive therapy with intravenously administered nimodipine: a multicenter, double-blind, dose-comparison study. Neurosurgery 26: 458
11. Cahn J (1985) Nimodipine - pharmacological and clinical properties. Proceedings I Nimotop Symposium Munich, Betze et al. (eds) Schattauer, Stuttgart, pp 137-140
12. Mickisch GH, Kossig J, Keilhauer G, Schlick E, Tschada RK, Alken PM (1990) Effects of calcium antagonists in mutlidrug resistance primary human renal carcinomas. Cancer Res 50: 3670-3674
13. Williams C (1992) Current issues in cancer: ovarian and cervical cancer. BMJ 304: 1501-1504
14. Smyth JF, Perren T, Wilkinson R, Prescott RJ, Quinn KJ, Tedeschi M (1994) Cisplatin and glutathione: a phase III, double-blind, randomised study in stage I-IV ovarian cancer. Ann Oncol 5 [Suppl 8]: 2
15. Cascinu S, Del Ferro E, Catalano G (1994) Neuroprotective effect of reduced glutathione on cisplatin based chemotherapy in advanced gastric cancer: a double-blind randomised trial. Ann Oncol 5 [Suppl 8]: 80
16. Dellafior-Weiss E, Blommaert F, Gill I, Muggia FM (1994) Amifostine (WR 2721) protects from bone marrow toxicity of combinations of cisplatin and carboplatin without decreasing platinum-DNA adduct formation. Ann Oncol 5 [Suppl 5]: 125
17. Treskes M, Vijgh WJ van der (1993) WR2721 as a modulator of cisplatin and carhoplatin induced side effects in comparison with other chemoprotective agents: a molecular approach. Can Chem Pharmacol 33: 93-106
18. Hamers FPT, Pette C, Bravenboer B, Vecht CJ, Neijt JP, (1993) Cisplatin induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766. Cancer Chemotherapy Pharmacol 32: 162-166
19. Neijt J, Van der Burg M, Vecht C, Tijssen C, Nooy A, Vermorken J, Van Oosterom A, Van Houwelinger J, Gispen W (1994) A double-blind randomised study with ORG-2766, an ACTH (4-9)analog, to prevent cisplatin neuropathy. Proc Am Soc Clin Oncol 13: 261
20. McGuire WP, Hoskins WJ, Brady MF, et al. (1993) A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/taxol (PT) in advanced ovarian cancer (AOC) (abstract 808). Proc Am Soc Clin Oncol. 12: 255
21. Chaudry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35: 304-311